Hema-seq reveals genomic aberrations in a rare simultaneous occurrence of hematological malignancies.
CP: Cancer biology
CP: Genetics
Journal
Cell reports methods
ISSN: 2667-2375
Titre abrégé: Cell Rep Methods
Pays: United States
ID NLM: 9918227360606676
Informations de publication
Date de publication:
23 Oct 2023
23 Oct 2023
Historique:
received:
22
11
2022
revised:
24
05
2023
accepted:
21
09
2023
medline:
30
10
2023
pubmed:
19
10
2023
entrez:
18
10
2023
Statut:
ppublish
Résumé
Co-occurrence of multiple myeloma and acute myelogenous leukemia is rare, with both malignancies often tracing back to multipotent hematopoietic stem cells. Cytogenetic techniques are the established baseline for diagnosis and characterization of complex hematological malignancies. In this study, we develop a workflow called Hema-seq to delineate clonal changes across various hematopoietic lineages through the integration of whole-genome sequencing, copy-number variations, cell morphology, and cytogenetic aberrations. In Hema-seq, cells are selected from Wright-stained slides and fluorescent probe-stained slides for sequencing. This technique therefore enables direct linking of whole-genome sequences to cytogenetic profiles. Through this method, we mapped sequential clonal alterations within the hematopoietic lineage, identifying critical shifts leading to myeloma and acute myeloid leukemia (AML) cell formations. By synthesizing data from each cell lineage, we provided insights into the hematopoietic tree's clonal evolution. Overall, this study highlights Hema-seq's capability in deciphering genomic heterogeneity in complex hematological malignancies, which can enable better diagnosis and treatment strategies.
Identifiants
pubmed: 37852254
pii: S2667-2375(23)00281-3
doi: 10.1016/j.crmeth.2023.100617
pmc: PMC10626221
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
100617Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests A.C.L., S.L., and S.K. hold shares in Meteor Biotech Co., Ltd.
Références
Science. 2012 Dec 21;338(6114):1622-6
pubmed: 23258894
Nat Commun. 2017 Jul 20;8(1):84
pubmed: 28729688
Cell. 2005 Apr 22;121(2):295-306
pubmed: 15851035
J Cell Physiol. 1991 Sep;148(3):446-56
pubmed: 1655817
BMC Cancer. 2015 Oct 16;15:724
pubmed: 26474569
Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5261-6
pubmed: 11959976
Nat Methods. 2017 Feb;14(2):167-173
pubmed: 28068316
Leuk Res. 2019 Oct;85:106210
pubmed: 31470354
Proc Natl Acad Sci U S A. 2021 Jun 15;118(24):
pubmed: 34099548
Genome Biol. 2018 Oct 8;19(1):158
pubmed: 30296938
PLoS One. 2017 Jul 19;12(7):e0181163
pubmed: 28723968
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
Lancet. 2008 Jun 14;371(9629):2039-41
pubmed: 18555915